scholarly journals Alzheimer’s Disease: Current and Future Treatments. A Review

2014 ◽  
Vol 2 (2) ◽  
pp. 56-63
Author(s):  
Evelyn Chou
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cholinesterase Inhibitors ◽  
Neurodegenerative Disorder ◽  
Nmda Antagonists ◽  
Disease Modifying Drugs ◽  
Plaque Deposition ◽  
The Future ◽  
Disease Modifying ◽  
Future Treatments

Alzheimer’s disease (AD) is a currently incurable neurodegenerative disorder whose treatment poses a big challenge. Proposed causes of AD include the cholinergic, amyloid and tau hypotheses. Current therapeutic treatments have been aimed at dealing with the neurotransmitter imbalance. These include cholinesterase inhibitors and N-Methyl-D-aspartate (NMDA) antagonists. However, current therapeutics have been unable to halt AD progression. Much research has gone into the development of disease-modifying drugs to interfere with the course of the disease. Approaches include secretase inhibition and immunotherapy aimed at reducing plaque deposition. However, these have not been successful in curing AD as yet. It is believed that the main reason why therapeutics have failed to work is that treatment begins too late in the course of the disease. The future of AD treatment thus appears to lie with prevention rather than cure. In this article, current therapeutics and, from there, the future of AD treatment are discussed.

The importance of high quality trials of cognitive interventions in Alzheimer's disease

2016 ◽  
Vol 28 (5) ◽  
pp. 705-706 ◽  
Author(s):  
Jonathan Huntley ◽  
Robert Howard
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cholinesterase Inhibitors ◽  
Evidence Based ◽  
High Quality ◽  
Disease Modifying Drugs ◽  
Cognitive Interventions ◽  
Potential Efficacy ◽  
Disease Modifying ◽  
Drug Interventions

Currently available treatments for Alzheimer's disease (AD) are disappointing and their modest benefits do not reflect the increased understanding of the condition that has arisen from the last 50 years of research or the huge investments made by the pharmaceutical industry and academia in developing therapies. Cholinesterase inhibitors and memantine are evidence-based symptomatic treatments that offer benefits at the margins of clinical significance, but successive failures in trials of putative disease-modifying drugs have led researchers to investigate the potential efficacy of non-drug interventions. Exercise and cognitive-based interventions have received the most attention, but we are still a long way from understanding whether any can offer real benefit to patients with AD (Huntley et al., 2015).

scholarly journals Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

CNS Drugs ◽  
2018 ◽  
Vol 32 (12) ◽  
pp. 1085-1090 ◽  
Author(s):  
Jacoline C. Bouvy ◽  
Pall Jonsson ◽  
Diana O’Rourke ◽  
Antonella Santuccione Chadha ◽  
Niklas Hedberg ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Health Technology Assessment ◽  
Technology Assessment ◽  
Health Technology ◽  
Disease Modifying Drugs ◽  
Disease Modifying

scholarly journals Combination Therapy in Moderate to Severe Alzheimer’s Disease - Overview and Discussion Points for the Future

2011 ◽  
Vol 6 (4) ◽  
pp. 228
Author(s):  
José L Molinuevo ◽  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Combination Therapy ◽  
Receptor Antagonist ◽  
Cholinesterase Inhibitors ◽  
Current Data ◽  
Aspartate Receptor ◽  
The Future

Two effective symptomatic therapies are available for Alzheimer’s disease: the cholinesterase inhibitors (ChEIs) and memantine, an N-methyl-D-aspartate receptor antagonist. Current data demonstrate that combination therapy with memantine and a ChEI produces symptomatic benefits in all domains of AD. The benefits of combination therapy are greater than those of ChEI monotherapy, are sustained long term and appear to increase with time.

Non-cognitive outcomes in trials of disease-modifying drugs for Alzheimer's disease

2012 ◽  
Vol 3 (1) ◽  
pp. 37-42 ◽  
Author(s):  
D. Zekry ◽  
C.E. Graf ◽  
S.V. Giannelli ◽  
G. Gold ◽  
J.-P. Michel
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Outcomes ◽  
Disease Modifying Drugs ◽  
Disease Modifying

scholarly journals New Approacher in the Development of Alzheimer’s Disease Modifying Drugs

2021 ◽  
pp. 88
Author(s):  
◽  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Tau Protein ◽  
Phase Iii ◽  
Disease Modifying Drugs ◽  
Phase Iii Clinical Trials ◽  
Research Level ◽  
Disease Modifying ◽  
Pathological Stages

Introduction: Alzheimer’s disease is a more common neurodegenerative disease, affecting 25 million people worldwide, or accounting for about 60 to 70% of all dementia cases. There is currently no exact mechanism to explain the pathophysiology of Alzheimer’s disease, however, cascading metabolic amyloid and post-translational review of tau protein are used as major hypotheses. Objective: To demonstrate in the literature new approaches in the development of Alzheimer’s disease modifiers. Methodology: For the accomplishment of this study made in the bibliographical survey of scientific literature and respect to the approached subject, in the databases PUBMED, ScienceDirect, Scielo and Scopus. Results: Alzheimer’s disease-modifying drugs are not yet available, but many patients may, however, develop phase III clinical trials and are intended to modify as pathological stages leading to the disease. As disease-modifying therapies under study, these changes also affect Aβ and tau protein and also cause inflammation and oxidative damage. The results obtained in the clinical trials performed were positive and promising and are still under study. The results show that there is still a long way to go in the development of Alzheimer’s disease modifying drugs. Conclusion: The results demonstrated that there is still a long way to go in the development of Alzheimer’s disease modifying drugs, but nevertheless levels at the research level should be continued in order to improve the pathophysiology of the disease and find an effective treatment for this disease the same.

scholarly journals ROLE OF THE HYPOTHALAMIC-PITUITARY-GONADAL SYSTEM IN THE PATHOGENESIS OF ALZHEIMER’S DISEASE

2018 ◽  
Vol 18 (1) ◽  
pp. 16-26
Author(s):  
O O Masalova ◽  
S B Kazakova ◽  
N S Sapronov
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Sex Steroids ◽  
Cholinesterase Inhibitors ◽  
Significant Contribution ◽  
Nmda Antagonists ◽  
Degenerative Diseases ◽  
Promising Area ◽  
Serious Disease

Alzheimer's disease (AD) is the most common from degenerative diseases of cerebrum which lead to the development of dementia. Because the exact causes of contraction of Alzheimer's disease (AD) are unknown, there is no adequate etiotropic therapy for this serious disease. Modern drugs present on the market, including cholinesterase inhibitors and NMDA antagonists, only alleviate symptoms without affecting the progression of AD. The review presents the results of modern studies confirming the significant contribution of gonadotropinreleasing hormone, gonadotropins and sex steroids to the development of mental aging. It is emphasized that the study of the role of the hypothalamic-pituitary-gonadal system in the etiopathogenesis of AD is certainly a promising area of psychoneuroendocrinology, which, perhaps, will lead to the development of new approaches to the treatment of this neurodegenerative disease. The contradictoriness of the data of a number of studies is noted and discussed.

Taking the Next Steps in the Treatment of Alzheimer's Disease: Disease-Modifying Agents

CNS Spectrums ◽  
2008 ◽  
Vol 13 (S3) ◽  
pp. 11-14
Author(s):  
Stephen Salloway
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Neurodegenerative Disorder ◽  
Disease Process ◽  
The United States ◽  
Disease Modification ◽  
Disease Modifying ◽  
New Treatment ◽  
Disease Modifying Agents ◽  
Disease Modifying Treatment

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder in the United States and the number of AD patients is increasing at an alarming rate. There is no cure for AD and the currently available treatments are symptomatic, providing only limited effects on disease pathophysiology and progression. An overwhelming need exists for therapies that can slow or halt this debilitating disease process. Disease modification in AD has been defined from patient-focused, regulatory, and neurobiological perspectives. The latter two of these perspectives rely largely on an interruption of the disease process and a clear demonstration of this interruption. As defined by Cummings, a disease-modifying treatment is a “pharmacologic treatment that retards the underlying process of AD by intervening in the neurobiological processes that constitute the pathology and pathophysiology of the disease and lead to cell death or dysfunction.” By this definition, the burden of confirmatory study is placed on any new treatment for which the claim of “disease modification” is to be made (Slide 1).

A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer’s Disease

2019 ◽  
Vol 26 (30) ◽  
pp. 5625-5648 ◽  
Author(s):  
Jan Korabecny ◽  
Katarina Spilovska ◽  
Eva Mezeiova ◽  
Ondrej Benek ◽  
Radomir Juza ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cholinesterase Inhibitors ◽  
Neurodegenerative Disorder ◽  
Memory Loss ◽  
Nmda Receptor Antagonist ◽  
Amyloid Burden ◽  
Ache Inhibitors ◽  
Intellectual Capacity ◽  
Β Amyloid

: Alzheimer’s Disease (AD) is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual deterioration of intellectual capacity. Its etiology has not been elucidated yet. To date, only one therapeutic approach has been approved for the treatment of AD. The pharmacotherapy of AD has relied on noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist - memantine, and acetylcholinesterase (AChE) inhibitors (AChEIs) - tacrine, donepezil, rivastigmine and galantamine. Donepezil was able to ameliorate the symptoms related to AD mainly via AChE, but also through reduction of β-amyloid burden. This review presents the overview of donepezilrelated compounds as potential anti-AD drugs developed on the basis of cholinergic hypothesis to act as solely AChE and butyrylcholinesterase (BChE) inhibitors.

Sign in / Sign up

Export Citation Format

Share Document